Background

Shanghai Pharma Dongying (Jiangsu) Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd. (SPH), specializes in the R&D and manufacturing of pharmaceuticals in the rapeutic areas such as neuromuscular blocking agents, cardiovascular and cerebrovascular diseases, and antipyretics & analgesics. The company’s key products include Cisatracurium Besylate for Injection (a neuromuscular blocker) and Perindopril Tablets (a cardiovascular drug).

SPH is a major pharmaceutical group listed on both the Shanghai and Hong Kong stock exchanges. It ranks among the Fortune Global 500, the top 50 global pharmaceutical companies, and is the second largest enterprise in China’s pharmaceutical industry.

Case detail

• Total Investment: USD 10 million

• Products: Drugs for cardiovascular, cerebrovascular, surgical, and anesthetic use